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Abstract 
BACKGROUND: Malignant Ovarian Germ Cell Tumors (MOGCT) most commonly occur in young women in the 
reproductive age group. Timely antenatal diagnosis and treatment of the tumour to enhance maternal and 
perinatal outcomes are the main challenges confronting the obstetrician and the gyne-oncologist.  
CASE PRESENTATION: Here we present three cases of pregnancy complicated with MOGCTs. The first case 
(immature teratoma) was complicated by maternal psychological symptoms consistent with stress and 
histopathological examination confirmed the diagnosis of premature ovarian failure (POF). The second case 
(dysgerminoma) preterm labour occurred as an obstetric complication, but the baby was born in good condition 
without IUGR. The third case (yolk sac tumour) treated with docetaxel (brexel)-carboplatin chemotherapy 
administration there was no maternal or fetal complication. At the end of the pregnancy and delivery, complete 
surgical staging and cytoreduction were performed, and no metastases were found.  
CONCLUSION: Optimal management strategies centre on a multi-disciplinary comprehensive team approach is 
critical resulting in better outcomes for the mother and the baby by avoiding complications. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Germ cell tumours (GCTs) originate from 
ovarian primordial germinal cells [1]. Malignant 
Ovarian Germ cell tumours occur most commonly in 
young women, usually unilateral (84.3%) and 
diagnosed at stage I (76.4%) [2]. The most common is 
dysgerminoma, the second is immature teratoma, and 
the third is the Yolk sac tumour. These tumours can 
be pure or mixed. The worldwide cancer prevalence in 
2012 according to the International Agency for 
Research on Cancer (IARC) was 6,657,518. The 
prevalence of ovarian cancer was 238,719 (3.6%) with 
overall mortality 151,917 (4.3%) [3]. Based on 
Dharmais Cancer Hospital data in 2010-2013, the 
incidence of ovarian cancer in Indonesia was 536, and 
126 women died. There were 8 cases of MOGCTs 
recorded at Pathology Department of Sanglah 
Hospital in 2016 to 2017 which consisted of 1 case of 
dysgerminoma, 5 cases of immature teratoma, 1 case 
of yolk sac tumour, and 1 case of mixed GCTs. Three 
cases of MOGCTs in pregnancy will be described in 
this report. The incidence of MOGCTs in pregnancy is 
very rare which 1 in 12,500-25,000 pregnancies [4]. 
Prognosis is dependent on histopathological tumour 
grading [2]. Decision-making regarding timing, mode, 
and place of delivery should be made by a 
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comprehensive team approach which will reduce 
maternal and perinatal morbidity and mortality [3], [4].
 
The incidence of gynaecological cancer over the past 
four decades has been rising associated with the 
trend of delayed childbearing [5].
 
As a result, the 
average age of primigravidae increased thus raising 
the risk of ovarian cancer and ovarian cancer during 
pregnancy. 
We present three cases of pregnancy 
complicated with MOGCTs. All cases were delivered 
at term after conservative primary surgery performed 
involving unilateral salpingo-oophorectomy in late mid-
trimester followed by chemotherapy until delivery and 
then surgical staging and debulking at relaparotomy 
after delivery of the baby. Surgical staging was 
conducted according to the FIGO Staging 
classification of ovarian tumours. 
 
 
Case 1 
 
A 31 y.o. Multigravida (G2P1A0) at 8 weeks 1 
day (8w1d) single/life gestation with solid ovarian 
tumour referred by the obstetrician to Obstetric and 
Gynecologic Policlinic of Sanglah Hospital, Denpasar. 
The pelvic examination found an adnexal tumour 
which increased progressively in size from 15 x 15 cm 
at 8w1d gestational age (GA) to 30 x 30cm at 19w5d 
GA, which was solid, with an irregular surface, mobile, 
and painful. Tumor marker levels were raised, AFP: 
699.9 IU/mL (normal level at 2
nd
 trimester: 22-93 
IU/mL), CA-125: 285.4 U/mL (normal level at 2
nd
 
trimester: < 35 U/mL), LDH: 579 U/L (normal level at 
2
nd
 trimester: 240-480). The patient had primary 
surgery (left oophorectomy, cytological test, and 
omentectomy) at 19w5d GA with minimal 
manipulation of the uterus. A midline abdominal 
incision performed, and an operation, a unilateral solid 
ovarian tumour identified 40 x 40cm in size with an 
irregular surface, arising from the left ovary with 
omental adhesions requiring adhesiolysis despite 
rupture of the tumour, it was successfully removed 
(Figure 1).  
 
Figure 1: Immature Teratoma Ultrasound (US) and Macroscopic 
Finding Durante Operation. CASE 1: A. US showed 
hypohyperechoic left adnexal mass which cannot reach totally 
inside probe range at 19w5d GA, irregular border, unsmooth 
surface; B. uterine size appropriate with 18-20 weeks GA, left 
Fallopian tube was normal, post-oophorectomy; and C. Lobulated 
solid mass with internal multiseptal cystic mass 
 
Internal abdominal and genitalia organ 
evaluation of uterus, size/consistency appropriate 18-
20 weeks GA, right and left Fallopian tube to seem 
normal, right ovarium seems normal, no nodules on 
the peritoneum, omentum, and liver. 
Histopathological assessment of left ovary 
was a grade II immature teratoma with immature 
components consisting of neuro-epithelial tubule and 
immature fat tissue; there was no evidence of 
malignant cell/immature component cell spreading on 
peritoneal fluid cytology. The patient’s tumour was 
designated as a Stage IC1 grade II Ovarian immature 
teratoma (FIGO). An MRI conducted at 25w3d 
gestation without evidence of tumour spreading. After 
appropriate consultation of the multidisciplinary team, 
four courses of Bleomycin-Etoposide-cisplatin (BEP) 
chemotherapy regimen treatment was instituted 
(starting at 27w2d gestation), with two weeks follow 
up of fetal well-being with USG fetal scanning and 
fetal well-being every 2 weeks after chemotherapy 
was instituted along with routine NST after 34 weeks’ 
gestation. Chemotherapy was paused 2 weeks before 
labour at 37w 6d gestation. The pregnancy continued 
until term and at gestation age 40w2d a female baby, 
2700 gram, was delivered vaginally following the 
spontaneous onset of labour. At delivery, the baby 
had an Apgar score 7-8, with no evidence of 
congenital abnormality. Secondary surgery 
(relaparotomy complete surgical staging) was 
performed on day 58 postpartum. The surgeon 
performs a Total Abdominal Hysterectomy (TAH), left 
salpingectomy, right salpingo-oophorectomy, bilateral 
pelvic and paraaortic lymphadenectomy, 
omentectomy and peritoneal biopsy (bilateral 
paracolic- and prevesical peritoneum). 
Histopathological examination revealed nodules 
containing only mature glial components on the 
peritoneum (prevesical and cavum Douglas), with no 
evidence of malignant cells or metastases. 
 
 
Case 2 
 
A 24-year old pregnant woman was sent by 
Karangasem Hospital to Sanglah Hospital Denpasar 
with a chief complaint of dyspnea with a swollen 
abdomen for 11 days before admission. The patient 
was in her third pregnancy at 29w gestation with a 
solid ovarian tumour. Tumour marker levels were 
raised, AFP: 135.48 IU/mL, CA-125: 113.4 U/mL, 
RMI: 340.32, Human Epididymis Protein 4 (HE4): 
68.9, ROMA: 99.37%. Corticosteroids were 
administered before the planned surgical procedure to 
enhance fetal lung maturation, and tocolytics were 
also administered. Utrogestan orally 2 x 200 mg was 
given 24 hours before surgery and continued for 48 
hours post-laparotomy.  
The patient had primary surgery (Laparotomy 
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left salpingo-oophorectomy and omentectomy, frozen 
section and cytological test) at 30w gestation through 
a midline abdominal incision. The operation revealed 
a solid ovarian mass admixed with a cystic component 
19 cm x 16 cm x 13 cm in size. Internal abdominal 
evaluation of the uterus was consistent with 30w 
gestation, the right and left Fallopian tubes were 
normal, the right ovary was normal, and there were no 
nodules on the peritoneum, omentum, and liver 
(Figure 2). The result of the histopathological 
assessment of left ovary was a dysgerminoma with a 
round to oval shape atypical cells separated with 
complex thin fibrous tissue septal network. Ascitic fluid 
cytology was positive for malignant cells, but no 
malignant cells were found in the momentum. The 
patient was staged as a FIGO Stage IC 
dysgerminoma ovarian cancer. No fetal anomalies 
were detected on feto-maternal ultrasound 
examination before treatment.  
 
Figure 2: Dysgerminoma Ultrasound and Macroscopic Finding 
Durante Operation. Case 2. A. USG showed hypo-hyperechoic left 
adnexa mass 11.17x8.16 with papillae at 29w2d GA; B. and C. 
Durante operation: solid mass mixed with cystic 19 cm x 16 cm x 13 
cm in size, arising from left ovarium 
 
Following primary surgery, the patient 
received 4 courses of BEP regimen (starting at 33w1d 
gestation), and she was planned to have a re-
laparotomy with surgical staging at the time of 
caesarean section at 38-weeks gestation age. 
However, the patient began in labour spontaneously 
at 35 weeks’ gestation and delivered vaginally with the 
baby, a male, 2100 g with Apgar scores of 7 and 8, 
and Ballard scores of 28 equivalent to 35-36w 
gestation. The placenta appeared normal at the time 
of delivery, and histopathological examination was not 
performed. Postpartum follow up was uneventful. No 
signs of myelosuppression of the baby were found, 
with haemoglobin level being 15,9 g/dL. The baby was 
not breastfed during the period of maternal 
chemotherapy. Abdominal USG was performed after 
delivery which demonstrated no spread of the tumour. 
Re-laparotomy surgical staging was performed at 42 
days postpartum, and chemotherapy continued until 
completion of the 4 courses.  
It was decided to perform TAH and right 
salpingo-oophorectomy. Histopathological 
examination revealed no evidence of malignancy. The 
patient advised to have a routine physical check-up, 
ultrasonography, CA 125 and AFP serum tumour 
markers every 3 months in the first year which normal. 
The baby is now 2 y.o., in good condition and growing 
normally.  
Case 3 
 
A 27-year old pregnant woman referred to 
Sanglah Hospital by a provincial hospital from West 
Nusa Tenggara with a diagnosis of 17–18 weeks’ 
gestation pregnancy and ovarian cyst suspicious of 
malignancy.  
 USG revealed a single fetus, fetal heart and 
movements were present, breech presentation, with 
18w5d GA. At 19–20 weeks GA an ovarian cyst 
suspicious of malignancy (RMI: 400.80) confirmed 
and based on that finding the RMI was 400. A 
laparotomy was a right salpingo-oophorectomy, 
omentectomy and appendicectomy performed. 
Cytological examination of the ascitic fluid revealed 
seeding of mucinous adenocarcinoma, and the FZ 
result was mucinous adenocarcinoma. The result of 
histopathological examination of paraffin-embedded 
tissue was a Yolk Sac ovarian tumour (reticular and 
glandular pattern) (Figure 3). After pathological 
review, a Yolk Sac tumour of right ovary was 
confirmed with diagnosis G2P1001 21w3d gestation 
singleton pregnancy with an ovarian cancer FIGO 
stage IC post SOD, omentectomy, appendicectomy. 
 
Figure 3: Microscopy of Immature Teratoma, Dysgerminoma, and 
Yolk Sac Tumor. A: Immature teratoma, consist of immature 
component/neuro-epithelial rosette and tubules (red arrow), mature 
glial tissue which pointed with green arrow, and another mature 
mesodermal component. B: Dysgerminoma, consist of round to oval 
atypical cell separated with complex thin fibrous tissue septal 
network which have rich lymphocyte infiltrate (red arrow). C: Yolk 
sac tumor, consist of cuboidal to columnar atypical cell forming 
gland-like structure, in part have clear cytoplasm forming glandular 
pattern (red arrow) 
 
 Docetaxel (Brexel)–carboplatin given for 6 
courses. Follow up of fetal well being performed by 
the Feto-maternal Division every 2 weeks until 
chemotherapy was completed. Fetal scanning was 
performed at gestation age 26w 5d. No major 
congenital anomaly was found. Monitoring with NST 
was started at 35 weeks’ gestation and remained 
normal. Chemotherapy was ceased 3 weeks before a 
planned caesarean section. This was done to allow 
time for recovery of the bone marrow of mother and 
baby.  
The final diagnosis was FIGO ovarian cancer 
stage IC post TAH + BSO + omentectomy + 
appendicectomy, and post-chemotherapy. Patient 
advised to undergo routine physical examination, 
ultrasonography, CA 125 and serum AFP every month 
for the first 3 months and then 6 monthly for 2 years.  
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Discussion 
 
In our case series, the first case was a 31 y.o 
pregnant woman with immature teratoma, the second 
case was a 24 y.o pregnant woman with a 
dysgerminoma, and the third case was a 27 y.o 
pregnant woman with a yolk sac tumour — the 
characteristics of the cases described in Table 1. 
Table 1: Table of Case Illustration  
Criteria  Cases  
First Second Third 
Maternal Age 31 y.o 24 y.o 27 y.o. 
Patient finding Abdomen enlarged 
at 8w 1d gestation 
Abdomen enlarged 
& dyspneu at age 
29w gestation 
Abdomen enlarged at 
19-20w 
gestation 
Ultrasonography 
Finding 
 
 
Hypo-hyperechoic 
mass, sircuscribed, 
rough surface, 
papillary, with septa 
Hypo-hyperechoic 
mass, papillary 
 
Hypo-hyperechoic 
mass, with septa 
 
 
Tumor Marker 
(-) 
(-) 
AFP: 699.9 
CA 125: 113.4 
RMI: 340.32 
AFP: 135.48 
CA 125: 400.8; 
RMI : 400.8 
(-) 
Antenatal Surgery 
time/type 
 
 
19w 5d, 
left oophorectomy, 
omentectomy 
30 w, 
Left salphingo-
oophorectomy - FZ 
21w, 
Right salphingo-
oophorectomy-FZ,  
Omentectomy,  
Appendisectomy 
Durante Operation 
Finding 
 
 
Prominent solid 
component, 40x40 
cm, lobulated, with 
cystic component, 
multisepta 
Solid mass with 
cystic component, 
19x16x13 cm 
 
Solid mass with cystic 
component 
FIGO Stage IC1 IC IC 
Histophatology Type Immature Teratoma 
grade II 
Dysgerminoma Yolk sac tumor 
Metastase Evaluation MRI (no metastase) USG (no metastase) (-) 
Chemotherapy 
time/type 
 
BEP 4 series at 
27w2d gestation 
BEP 4 series at 33w 
gestation 
 
Docetaxel (Brexel) – 
Carboplatin 6 series at 
21w 3d 
Complication 
maternal after 
chemotherapy 
POF (-) (-) 
Complication fetal 
after chemotherapy 
 
(-) 
 
Preterm delivery 
 
(-) 
Mode of delivery/time Vaginal delivery At 
40w 2d gestation 
Vaginal delivery At 
35w gestation 
CS At 38w gestation, 
Placental metastasis (-) Not assesed Not assesed 
 
Fetal Outcome 
 
2700 g (persentile 
10-25), vigorous, no 
congenital 
abnormality 
2105 g (persentile 
25-75),  vigorous, no 
congenital 
abnormality 
3165 g (persentile 50-
75), vigorous, no 
congenital 
abnormality 
Surgical staging 
time/type 
 
Complete surgical 
Staging at 58 d 
postpartum 
Cytoreduction at 42 
d postpartum, 
 
Cytoreduction at the 
same with CS, at 39w 
Breast feeding (-) (-) (-) 
Survival 5 years 62% >90% 90% 
 
 
Diagnosis of MOGCTs in the young female is 
challenging using tumour markers (AFP, LDH, hCG, 
CA125-RMI) and the US, with histopathological as the 
gold standard. Increased tumour markers level occur 
during pregnancy. Hence tumour markers level should 
be cautiously interpreted, and treatment strategies 
should not be based on these markers alone [8]. AFP 
produced initially by the fetal yolk sac and continued 
by the liver and digestive tract with a high AFP level 
associated with the suspicion of neural defect 
abnormalities such as spina bifida, anencephaly, 
oesophageal defect, and fetal abdominal separation 
failure. The AFP level decreased exponentially after 
primary ovarian tumour removal, and it concluded that 
the increased AFP level in this patient, originated from 
the primary tumour, and similarly with the other 2 
cases where no major structural abnormality found.  
The first case complicated by maternal 
psychological symptoms consistent with stress. The 
FSH level was high at 50.01 mU/L, but FSH has poor 
accuracy as a diagnostic marker in pregnancy for 
ovarian failure. The AMH is more reliable, and this 
plus the right ovarian atrophy (contralateral ovary) 
demonstrated on histopathological examination 
confirmed the diagnosis of premature ovarian failure 
(POF) as a possible contributor to her symptoms. 
Following immunohistochemistry (IHC) to detect 
estrogen receptors (ER) and progesterone receptors 
(PR) on affected left ovary (ovary with immature 
teratoma) it was concluded that hormone replacement 
therapy (HRT) could be safely given due to ER (-) and 
PR (+) [6]. With the second case, preterm labour 
occurred as an obstetric complication, but the baby 
was born in good condition without IUGR (percentile 
25-50). The third case (yolk sac tumour) treated with 
docetaxel (brexel)-carboplatin chemotherapy 
administration there was no maternal or fetal 
complication. Carboplatin a second generation 
platinum-based drug was shown by Mir et al., to be a 
safer drug compared to cisplatin with no apparent fetal 
malformation or maternal toxicity [2], [7]. 
In our case series, all the babies had normal 
weight. Laboratory findings at first week after birth not 
found any evidence of transient myelosuppression. It 
was suggested that routinely follow up of the baby 
every 6 months needed for the first 2 years as a 
minimum. At the end of pregnancy and delivery, 
complete surgical staging and cytoreduction were 
performed, and no metastases were found. 
 
Management of Patient 
Conservative Surgery 
The treatment of MOGCTs in pregnancy is by 
primary conservative surgery and chemotherapy 
followed by a complete surgical staging and 
cytoreduction post-delivery. Removal of an adnexal 
mass at pregnancy as conservative surgery is best 
done through a midline abdominal incision with a 
unilateral oophorectomy and cystectomy, 
omentectomy, and peritoneal fluid cytology to confirm 
the histopathological diagnosis.
 
An adnexal mass 
detected in the first trimester of pregnancy in a patient 
with an ovarian lesion of suspected low malignant 
potential can be treated with conservatively. However 
in women with an ovarian mass with septae, solid 
areas, papillae, nodules, or persisting until 16 weeks 
gestation, surgery may be postponed until the second 
trimester (16-18 weeks gestation), as it is a ‘safe 
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period’ for the fetus and the best period to perform 
surgical intervention of an adnexal mass as the 
spontaneous abortion risk is low (up to 10%), and an 
acceptable operative field is still available, allowing 
minimal uterine manipulation and lowering the risk of 
obstetric complications. The surgery can be 
performed ideally at 24-26 weeks gestation [9].  
Adnexal mass surgery in the third trimester 
increases the incidence of preterm labour up to 22% 
and is associated with adverse obstetric outcome. 
Adnexal masses detected after 35 weeks gestational 
age can be removed at caesarean section [9].
 
Other 
indications for operative management include acute 
abdominal symptoms such as pain, rupture, and 
torsion. Routine tocolytic administration is still 
controversial but can be considered if there are signs 
of preterm labour [10, [11].
  
There is still a chance for spontaneous 
vaginal delivery with surgical staging completed 3 to 6 
weeks after delivery. If operative delivery chosen then 
cytoreduction may be done at the same time as 
caesarean section. Re-laparotomy to complete 
surgical staging or cytoreduction is recommended as 
these may be limited during the pregnancy period, 
and there are reports of rapid growth and recurrence 
of OMGCTs during the puerperium. 
 
Chemotherapy 
The most challenging problem of 
chemotherapy during pregnancy is to obtain optimal 
chemotherapy without disturbing fetal growth and 
development with gestation age as a consideration 
[7].
 
Malignant ovarian GCTs are sensitive to 
chemotherapy and radiotherapy. Chemotherapy 
combination is usually used as adjuvant if the choice 
to continue the pregnancy. The choice of treatment 
determined by tumour type and its histological 
features to obtain the best response and improve 
prognosis. Bleomycin-etoposide-cisplatin is the first 
line chemotherapy for MOGCTs with treatment every 
3 weeks for 3-4 courses. Patients have a good 
prognosis after cisplatin-based chemotherapy 
combination [13].
 
One review of the literature found that BEP 
chemotherapy was not associated with increasing 
congenital malformations [11].
 
Another study the use 
of cisplatin suggested an association with hearing loss 
(2,7%), ventriculomegaly (2%), IUGR and prematurity 
(8.3%), oligohydramnios (5.6%), anaemia (5.6%), 
micro-ophthalmia (2.8%) [6], [12]. Additionally, BEP 
may cause an imbalance of procoagulant-
anticoagulant associated with disseminated 
intravascular coagulation, thrombosis, and bleeding 
(cisplatin-associated with liver vessel endothelial 
damage which causes ischemia and infarction; 
bleomycin associated with disturbance of blood 
clotting cascade; etoposide associated with 
thrombocytopenia).  
Labour and Delivery 
The optimal labour time is after 35-37 weeks 
and 3 weeks post-chemotherapy to avoid 
chemotherapy accumulation and to allow recovery 
from possible bone marrow suppression of mother 
and baby [13].
 
Mode of delivery preference was 
spontaneous vaginal rather than caesarean section. 
The benefits of spontaneous delivery are less blood 
loss, less operative risk and low infection risk with 
shorter length of stay at the hospital. Women having 
chemotherapy not recommended breastfeeding due to 
the risk of chemotherapy excreted through breast milk 
which could result in neonatal pancytopenia. Placental 
metastases often mentioned as a curiosity but 
occurred very rarely with only 80 cases reported since 
1866.
 
The incidence of fetal metastases is even more 
rare with only 11 cases reported in the literature [15].
 
 
Prognosis  
The staging system used was the 
International Federation of Gynecology and Obstetrics 
(FIGO) 2014 with three ovarian cancers being stage 
IC. Malignant germ cell tumour has a better prognosis 
(> 95%) if detected at stage I. Advanced MOGCTs 
very aggressive, but prognosis may still be good if not 
delay chemotherapy. Prognosis of immature ovarian 
teratoma is governed by grade and stage. Five-year 
survival rate overall for all stages is 70-80%, and 90-
95% for stage I patients. The five-year survival rate is 
82%, 62%, and 30% respectively in patients with 
grades 1, 2, and 3 treated with optimum 
chemotherapy. Recurrence occurs on 36% during 5 
years follow up, and the survival rates of early and 
advanced dysgerminomas are 95 and > 80%, 
respectively. Stage 1a dysgerminoma after unilateral 
salpingo-oophorectomy has a relapse rate of 10 to 
20% with overall survival rate 90-100%. Recurrence 
patients who undergo repeat chemotherapy still have 
a survival rate greater than 90% [5]. 
In conclusion, malignant ovarian germ cell 
tumours in pregnancy are rare but challenging. 
Optimal management strategies centre on a multi-
disciplinary comprehensive approach about diagnosis, 
primary surgery, chemotherapy, delivery, complete 
surgical staging, and neonatal care. Such an 
approach is critical resulting in better maternal and 
fetal outcomes by avoiding complications. 
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